EP4140479A4 - THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) - Google Patents

THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) Download PDF

Info

Publication number
EP4140479A4
EP4140479A4 EP21792108.9A EP21792108A EP4140479A4 EP 4140479 A4 EP4140479 A4 EP 4140479A4 EP 21792108 A EP21792108 A EP 21792108A EP 4140479 A4 EP4140479 A4 EP 4140479A4
Authority
EP
European Patent Office
Prior art keywords
covid
therapeutic
preventive agent
coronavirus disease
coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21792108.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4140479A1 (en
Inventor
Kiyoshi Kita
Kouichi Morita
Jiro Yasuda
Yasuteru Sakurai
Satofumi Kawata
Tohru Tanaka
Motoyasu TOMIOKA
Kiyotaka FUJINE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nagasaki University NUC
Neopharma Japan Co Ltd
Original Assignee
Nagasaki University NUC
Neopharma Japan Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagasaki University NUC, Neopharma Japan Co Ltd filed Critical Nagasaki University NUC
Publication of EP4140479A1 publication Critical patent/EP4140479A1/en
Publication of EP4140479A4 publication Critical patent/EP4140479A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21792108.9A 2020-04-22 2021-04-22 THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) Pending EP4140479A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020076370 2020-04-22
JP2020174820 2020-10-16
PCT/JP2021/016372 WO2021215517A1 (ja) 2020-04-22 2021-04-22 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の治療及び／又は予防剤

Publications (2)

Publication Number Publication Date
EP4140479A1 EP4140479A1 (en) 2023-03-01
EP4140479A4 true EP4140479A4 (en) 2024-05-29

Family

ID=78269312

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21792108.9A Pending EP4140479A4 (en) 2020-04-22 2021-04-22 THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19)

Country Status (5)

Country Link
US (1) US20230190690A1 (ja)
EP (1) EP4140479A4 (ja)
JP (2) JP7058026B2 (ja)
CN (1) CN115768415A (ja)
WO (1) WO2021215517A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101478237B1 (ko) * 2013-05-13 2014-12-31 주식회사 시온테크 선박용 굴뚝의 사다리 구조체

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041855A1 (en) * 1996-05-08 1997-11-13 New York Blood Center, Inc. Method for treating viral infections
US20150164838A1 (en) * 2012-07-19 2015-06-18 Sbi Pharmaceuticals Co., Ltd. Prophylactic/therapeutic agent for influenza virus infection
EP3281629A1 (en) * 2015-04-10 2018-02-14 SBI Pharmaceuticals Co., Ltd. Prophylactic/therapeutic agent for virus infections which comprises ala compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05008298A (es) 2003-02-04 2005-09-20 Yakult Honsha Kk Inhibidor de la proteina de resistencia a cancer de mama.
CA2515135A1 (en) 2003-02-04 2004-08-19 Kabushiki Kaisha Yakult Honsha Breast cancer-resistant protein inhibitor
EA014555B1 (ru) 2005-03-30 2010-12-30 Кабусики Кайся Якулт Хонса Ингибитор bcrp/abcg2
TW200927107A (en) 2007-12-03 2009-07-01 Yakult Honsha Kk ABCG2 inhibitor
AU2014283588A1 (en) 2013-06-18 2015-11-05 Nestec S.A. Filter unit for a capsule
TW202106293A (zh) * 2019-04-26 2021-02-16 日商日本紐翱醫藥股份有限公司 黃病毒（ｆｌａｖｉｖｉｒｕｓ）感染症治療劑
US10987329B1 (en) 2020-04-22 2021-04-27 Nadimpally Satyavarahala Raju Combination therapy for coronavirus infections including the novel corona virus (COVID-19)
US11883376B2 (en) 2020-04-22 2024-01-30 Nadimpally Satyavarahala Raju Viral infection treatment with 5-aminolevulinic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041855A1 (en) * 1996-05-08 1997-11-13 New York Blood Center, Inc. Method for treating viral infections
US20150164838A1 (en) * 2012-07-19 2015-06-18 Sbi Pharmaceuticals Co., Ltd. Prophylactic/therapeutic agent for influenza virus infection
EP3281629A1 (en) * 2015-04-10 2018-02-14 SBI Pharmaceuticals Co., Ltd. Prophylactic/therapeutic agent for virus infections which comprises ala compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MA LIN-LIN ET AL: "heme oxygenase-1 agonist CoPP suppresses influenza virus replication through IRF3-mediated generation of IFN-[alpha]/[beta]", VIROLOGY, vol. 528, 20 December 2018 (2018-12-20), pages 80 - 88, XP085613939, ISSN: 0042-6822, DOI: 10.1016/J.VIROL.2018.11.016 *
See also references of WO2021215517A1 *

Also Published As

Publication number Publication date
US20230190690A1 (en) 2023-06-22
JPWO2021215517A1 (ja) 2021-10-28
EP4140479A1 (en) 2023-03-01
JP2022008060A (ja) 2022-01-13
WO2021215517A1 (ja) 2021-10-28
CN115768415A (zh) 2023-03-07
JP7058026B2 (ja) 2022-04-21

Similar Documents

Publication Publication Date Title
DE50203788D1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2005009342A3 (en) Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
AU2003229923A1 (en) Curcumin for the prevention and/or treatment of tissue damage
WO2007121088A3 (en) Combinations of therapeutic agents for treating cancer
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
EP3753557A4 (en) PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES OR BONE DISEASES
EP4196113A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
AU2002323823A1 (en) Medicament for prevention and treatment of fracture and osteoporosis
EP4140479A4 (en) THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19)
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
AU2003221042A1 (en) Preventive or therapeutic agent for kidney disease
EP4166139A4 (en) AGENTS FOR THE PREVENTION OR TREATMENT OF ACTINIC SKIN DISEASES
WO2003039464A3 (en) Antimuscarinic aerosol
EP1441718A4 (en) CARBINOL FOR THE TREATMENT OF NEUROPATHIC FUNCTIONAL DISORDER
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
AU2003262230A1 (en) Preventive and/or therapeutic drugs for itch
PT1220676E (pt) Prevencao do cancro colorrectal
GB9930075D0 (en) Medicaments
WO2002039958A3 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
EP3939585A4 (en) PREVENTIVE OR THERAPEUTIC COMPOSITION FOR INFECTIOUS DISEASES WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
EP4104861A4 (en) THERAPEUTIC FOR TAUOPATHIES
WO2005020895A3 (en) Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240424

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20240419BHEP

Ipc: A61P 31/14 20060101ALI20240419BHEP

Ipc: A61K 45/00 20060101ALI20240419BHEP

Ipc: A61K 33/30 20060101ALI20240419BHEP

Ipc: A61K 33/26 20060101ALI20240419BHEP

Ipc: A61K 33/24 20190101ALI20240419BHEP

Ipc: A61K 33/06 20060101ALI20240419BHEP

Ipc: A61K 31/4985 20060101ALI20240419BHEP

Ipc: A61K 31/295 20060101ALI20240419BHEP

Ipc: A61K 31/197 20060101AFI20240419BHEP